Nicholaos C. Bellos

发表

ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine

D. Ward, K. Squires, E. Dejesus, 2012, HIV clinical trials.

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

M. King, S. Brun, J. Arribas, 2008, The Journal of infectious diseases.

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

K. Squires, E. Dejesus, N. Bellos, 2010, AIDS.

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.

G. D. Miralles, C. Cohen, M. Greenberg, 2005, The Journal of infectious diseases.

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

D. Fine, Kimberly Smith, N. Bellos, 2009, AIDS.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)*

D. Peterson, S. Swindells, R. Murphy, 2000, AIDS.

Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection

M. Wulfsohn, K. Squires, A. Pozniak, 2003, Annals of Internal Medicine.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Bernard Hirschel, Adriano Lazzarin, B. Hirschel, 2008, The New England journal of medicine.

Increased HIV infection rate among violent deaths: a mortuary study in the Republic of Congo

K. Squires, D. Berger, E. Dejesus, 2008, AIDS (London).

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

Edwin DeJesus, Jane Yeo, A. Gładysz, 2004, AIDS.

Similar Efficacy of Raltegravir When Used With or Without a Protease Inhibitor in Treatment-Experienced Patients

D. Ward, K. Mounzer, M. Gottlieb, 2011, HIV clinical trials.

Efficacy and safety of switching suppressed patients with elevated triglycerides from lopinavir/ritonavir or fosamprenavir/ritonavir to atazanavir/ritonavir or darunavir/ritonavir based therapy: The LARD study

K. Mounzer, D. Skiest, C. Cohen, 2012 .

Twice‐Daily Trizivir versus Combivir‐Abacavir in Antiretroviral‐Experienced Adults with Human Immunodeficiency Virus‐1 Infection: A Formulation‐Switch Trial

C. Farthing, M. Fischl, N. Bellos, 2003, Pharmacotherapy.

Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.

H. Kessler, S. Follansbee, D. Mildvan, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

R. C. Rose, Todd M. Allen, David S. Rubin, 2010, Science.

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America

L. Bekker, R. Wood, C. Orrell, 2008, AIDS.

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

J. Gallant, E. Daar, A. Clarke, 2017, Journal of acquired immune deficiency syndromes.

Background: Resistance to antiretroviral agents remains a lead- ing cause of treatment failure for patients infected with HIV-1.

M. Wulfsohn, K. Squires, A. Pozniak, 2003 .

Lamivudine 300 mg QD Versus Continued Lamivudine 150 mg BID with Stavudine and a Protease Inhibitor in Suppressed Patients

E. Dejesus, N. Bellos, M. Sension, 2002, HIV clinical trials.